Alx Oncology Holdings (ALXO) Net Equity Issued and Repurchased (2019 - 2026)

Alx Oncology Holdings has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $11000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 97.04% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 95.09% YoY) and the FY2025 annual result came in at $1.7 million, down 94.31% from the prior year.
• Net Equity Issued and Repurchased declined to $11000.0 in Q1 2026 per ALXO's latest filing, from $1.3 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $26.2 million in Q2 2024 and troughed at $11000.0 in Q1 2026.
• A 3-year average of $4.5 million and a median of $372000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased jumped 266.57% in 2025, then plunged 97.04% in 2026.
• Over 3 years, Net Equity Issued and Repurchased stood at $359000.0 in 2024, then surged by 266.57% to $1.3 million in 2025, then sank by 99.16% to $11000.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $11000.0, $1.3 million, and $372000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.